Altered macrophage differentiation and immune dysfunction in tumor development

Journal of Clinical Investigation

Volumn 117, Issue 5, 2007, Pages 1155-1166

  Sica, Antonio ^a   Bronte, Vincenzo ^b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; STAT6 PROTEIN; TOSYLARGININE METHYL ESTER;

AMINO ACID METABOLISM; ANGIOGENESIS; BONE MARROW CELL; CANCER RESEARCH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL HETEROGENEITY; CELL POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LEUKOCYTE DISORDER; MACROPHAGE; MOUSE STRAIN; MYELOPOIESIS; NATURAL KILLER T CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION;

ANIMALS; CELL DIFFERENTIATION; HUMANS; IMMUNE SYSTEM DISEASES; MACROPHAGES; NEOPLASMS;

EID: 34248172324     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI31422     Document Type: Review

References (124)

1. Mocellin, S., et al. 2004. Part I: Vaccines for solid tumours. Lancet Oncol. 5:681-689.
2. Rosenberg, S.A., Yang, J.C., and Restifo, N.P. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10:909-915.
3. Rabinovich, G.A., Gabrilovich, D., and Sotomayor, E.M. 2007. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25:267-296.
4. Serafini, P., Borrello, I., and Bronte, V. 2006. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 16:53-65.
5. Maier, T., Holda, J.H., and Claman, H.N. 1989. Natural suppressor cells. Prog. Clin. Biol. Res. 288:235-244.
6. Seung, L.P., Rowley, D.A., Dubey, P., and Schreiber, H. 1995. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc. Natl. Acad. Sci. U. S. A. 92:6254-6258.
7. Pekarek, L.A., Starr, B.A., Toledano, A.Y., and Schreiber, H. 1995. Inhibition of tumor growth by elimination of granulocytes. J. Exp. Med. 181:435-440.
8. Kusmartsev, S., and Gabrilovich, D.I. 2006. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol. Immunother. 55:237-245.
9. Gabrilovich, D. 2004. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4:941-952.
10. Gabrilovich, D.I., et al. 2007. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 67:425; author reply 426.
11. Gallina, G., et al. 2006. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8 T cells. J. Clin. Invest. 116:2777-2790. doi:10.1172/JCI28828.
12. Van Ginderachter, J.A., et al. 2006. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. Blood. 108:525-535.
13. Kusmartsev, S., and Gabrilovich, D.I. 2005. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J. Immunol. 174:4880-4891.
14. Tsuda, Y., et al. 2004. Three different neutrophil subsets exhibited in mice with different susceptibilities to infection by methicillin-resistant Staphylococcus aureus. Immunity. 21:215-226.
15. Zea, A.H., et al. 2005. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 65:3044-3048.
16. Schmielau, J., and Finn, O.J. 2001. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 61:4756-4760.
17. Bronte, V., et al. 1999. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J. Immunol. 162:5728-5737.
18. Melani, C., Chiodoni, C., Forni, G., and Colombo, M.P. 2003. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood. 102:2138-2145.
19. Kusmartsev, S., Nefedova, Y., Yoder, D., and Gabrilovich, D.I. 2004. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172:989-999.
20. Sinha, P., Clements, V.K., and Ostrand-Rosenberg, S. 2005. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J. Immunol. 174:636-645.
21. Terabe, M., et al. 2000. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1:515-520.
22. Terabe, M., et al. 2003. Transforming growth factor-{beta} production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198:1741-1752.
23. Bronte, V., and Zanovello, P. 2005. Regulation of immune responses by L-arginine metabolism [review]. Nat. Rev. Immunol. 5:641-654.
24. Gabrilovich, D.I., Velders, M.P., Sotomayor, E.M., and Kast, W.M. 2001. Mechanism of immune dysfunction in cancer mediated by immature gr-1(+) myeloid cells. J. Immunol. 166:5398-5406.
25. Otsuji, M., et al. 1996. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc. Natl. Acad. Sci. U. S. A. 93:13119-13124.
26. Huang, B., et al. 2006. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66:1123-1131.
27. Kusmartsev, S., Nagaraj, S., and Gabrilovich, D.I. 2005. Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J. Immunol. 175:4583-4592.
28. Bronte, V., et al. 1998. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J. Immunol. 161:5313-5320.
29. Serafini, P., et al. 2006. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 203:2691-2702.
30. Yang, R., et al. 2006. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res. 66:6807-6815.
31. Gordon, S. 2003. Alternative activation of macrophages. Nat. Rev. Immunol. 3:23-35.
32. Mantovani, A., et al. 2002. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23:549-555.
33. Mantovani, A., et al. 2004. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25:677-686.
34. Ganster, R.W., Taylor, B.S., Shao, L., and Geller, D.A. 2001. Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-kappa B. Proc. Natl. Acad. Sci. U. S. A. 98:8638-8643.
35. Kleinert, H., Schwarz, P.M., and Forstermann, U. 2003. Regulation of the expression of inducible nitric oxide synthase. Biol. Chem. 384:1343-1364.
36. Melillo, G., et al. 1995. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J. Exp. Med. 182:1683-1693.
37. Boutard, V., et al. 1995. Transforming growth factor-beta stimulates arginase activity in macrophages. Implications for the regulation of macrophage cytotoxicity. J. Immunol. 155:2077-2084.
38. Morrison, A.C., and Correll, P.H. 2002. Activation of the stem cell-derived tyrosine kinase/RON receptor tyrosine kinase by macrophage-stimulating protein results in the induction of arginase activity in murine peritoneal macrophages. J. Immunol. 168:853-860.
39. Jost, M.M., et al. 2003. Divergent effects of GMCSF and TGFbeta1 on bone marrow-derived macrophage arginase-1 activity, MCP-1 expression, and matrix metalloproteinase-12: a potential role during arteriogenesis. FASEB J. 17:2281-2283.
40. Munder, M., Eichmann, K., and Modolell, M. 1998. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J. Immunol. 160:5347-5354.
41. Raes, G., et al. 2005. Arginase-1 and Ym1 are markers for murine, but not human, alternatively activated myeloid cells. J. Immunol. 174:6561; author reply 6561-6562.
42. Munder, M., et al. 2006. Suppression of T cell functions by human granulocyte arginase. Blood. 108:1627-1634.
43. Rodriguez, P.C., and Ochoa, A.C. 2006. T cell dysfunction in cancer: role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress. Semin. Cancer Biol. 16:66-72.
44. Bronte, V., et al. 2003. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J. Immunol. 170:270-278.
45. Mazzoni, A., et al. 2002. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 168:689-695.
46. Apolloni, E., et al. 2000. Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. J. Immunol. 165:6723-6730.
47. Rodriguez, P.C., et al. 2004. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 64:5839-5849.
48. Rodriguez, P.C., Quiceno, D.G., and Ochoa, A.C. 2006. L-Arginine availability regulates T lymphocyte cell cycle progression. Blood. 109:1568-1573.
49. Fallarino, F., et al. 2006. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 176:6752- 6761.
50. Munn, D.H., et al. 2005. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity. 22:633-642.
51. Sinha, P., Clements, V.K., and Ostrand-Rosenberg, S. 2005. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res. 65:11743-11751.
52. Ezernitchi, A.V., et al. 2006. TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J. Immunol. 177:4763-4772.
53. Baniyash, M. 2004. TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat. Rev. Immunol. 4:675-687.
54. Bronte, V., et al. 2005. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J. Exp. Med. 201:1257-1268.
55. Sica, A., Schioppa, T., Mantovani, A., and Allavena, P. 2006. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer. 42:717-727.
56. Bingle, L., Brown, N.J., and Lewis, C.E. 2002. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 196:254-265.
57. Mantovani, A., et al. 1992. The origin and function of tumor-associated macrophages. Immunol. Today. 13:265-270.
58. Balkwill, F. 2003. Chemokine biology in cancer. Semin. Immunol. 15:49-55.
59. Pollard, J.W. 2004. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer. 4:71-78.
60. Mellman, I., and Steinman, R.M. 2001. Dendritic cells: specialized and regulated antigen processing machines. Cell. 106:255-258.
61. Yang, L., et al. 2004. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell. 6:409-421.
62. Lewis, C.E., and Pollard, J.W. 2006. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66:605-612.
63. Leek, R.D., et al. 2002. Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in human breast cancer. Cancer Res. 62:1326-1329.
64. Schioppa, T., et al. 2003. Regulation of the chemokine receptor CXCR4 by hypoxia. J. Exp. Med. 198:1391-1402.
65. Ceradini, D.J., et al. 2004. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 10:858-864.
66. Muller, A., et al. 2001. Involvement of chemokine receptors in breast cancer metastasis. Nature. 410:50-56.
67. Albina, J.E., et al. 2005. Macrophage arginase regulation by CCAAT/enhancer-binding protein beta. Shock. 23:168-172.
68. Morris, S.M., Jr. 2002. Regulation of enzymes of the urea cycle and arginine metabolism. Annu. Rev. Nutr. 22:87-105.
69. Semenza, G.L. 2003. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer. 3:721-732.
70. Karin, M., and Greten, F.R. 2005. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5:749-759.
71. Karin, M., and Lin, A. 2002. NF-kappaB at the crossroads of life and death. Nat. Immunol. 3:221-227.
72. Balkwill, F., Charles, K.A., and Mantovani, A. 2005. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 7:211-217.
73. Falkensammer, C., et al. 2006. IL-4 inhibits the TNF-alpha induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF-alpha to induce apoptotic and cytokine responses by RCC: implications for antitumor immune responses. Cancer Immunol. Immunother. 55:1228-1237.
74. Richmond, A. 2002. Nf-kappa B, chemokine gene transcription and tumour growth. Nat. Rev. Immunol. 2:664-674.
75. Saccani, A., et al. 2006. p50 nuclear factor-{kappa}B overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 66:11432-11440.
76. Sica, A., et al. 2000. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J. Immunol. 164:762-767.
77. Greten, F.R., and Karin, M. 2004. The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett. 206:193-199.
78. Pikarsky, E., et al. 2004. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 431:461-466.
79. Colombo, M.P., and Mantovani, A. 2005. Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion. Cancer Res. 65:9113-9116.
80. Kortylewski, M., et al. 2005. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11:1314-1321.
81. Biswas, S.K., et al. 2006. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood. 107:2112-2122.
82. Guiducci, C., et al. 2005. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65:3437-3446.
83. Rauh, M.J., et al. 2005. SHIP represses the generation of alternatively activated macrophages. Immunity. 23:361-374.
84. Mantovani, A., Sica, A., and Locati, M. 2005. Macrophage polarization comes of age. Immunity. 23:344-346.
85. Luo, Y., et al. 2006. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J. Clin. Invest. 116:2132-2141. doi: 10.1172/JCI27648.
86. Das, J., et al. 2001. A critical role for NF-kappa B in GATA3 expression and TH2 differentiation in allergic airway inflammation. Nat. Immunol. 2:45-50.
87. Moore, R.J., et al. 1999. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat. Med. 5:828-831.
88. Sica, A., et al. 2000. Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma. J. Immunol. 164:733-738.
89. Ghosh, P., et al. 1994. Alterations in NF kappa B/Rel family proteins in splenic T-cells from tumorbearing mice and reversal following therapy. Cancer Res. 54:2969-2972.
90. Yoshimura, A. 2006. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci. 97:439-447.
91. O'Shea, J.J., Pesu, M., Borie, D.C., and Changelian, P.S. 2004. A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat. Rev. Drug Discov. 3:555-564.
92. Dunn, G.P., Koebel, C.M., and Schreiber, R.D. 2006. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6:836-848.
93. Bach, E.A., Aguet, M., and Schreiber, R.D. 1997. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu. Rev. Immunol. 15:563-591.
94. Kaplan, D.H., et al. 1998. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. U. S. A. 95:7556-7561.
95. Lesinski, G.B., et al. 2003. The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse. J. Clin. Invest. 112:170-180. doi: 10.1172/JCI200316603.
96. Zhou, Y., Wang, S., Gobl, A., and Oberg, K. 2001. Interferon alpha induction of Stat1 and Stat2 and their prognostic significance in carcinoid tumors. Oncology. 60:330-338.
97. Torrero, M.N., et al. 2006. Stat1 deficiency in the host enhances interleukin-12-mediated tumor regression. Cancer Res. 66:4461-4467.
98. Hanada, T., et al. 2006. IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J. Exp. Med. 203:1391-1397.
99. Wang, T., et al. 2004. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10:48-54.
100. Nefedova, Y., et al. 2004. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol. 172:464-474.
101. Nefedova, Y., et al. 2005. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J. Immunol. 175:4338-4346.
102. Ostrand-Rosenberg, S., et al. 2002. Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent. J. Immunol. 169:5796-5804.
103. Langowski, J.L., et al. 2006. IL-23 promotes tumour incidence and growth. Nature. 442:461-465.
104. Watford, W.T., et al. 2004. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol. Rev. 202:139-156.
105. Serafini, P., et al. 2004. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 64:6337-6343.
106. Condeelis, J., and Pollard, J.W. 2006. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 124:263-266.
107. Talks, K.L., et al. 2000. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157:411-421.
108. Bolat, F., et al. 2006. Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: correlations with prognostic parameters. J. Exp. Clin. Cancer Res. 25:365-372.
109. Ueno, T., et al. 2000. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res. 6:3282-3289.
110. Kataki, A., et al. 2002. Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J. Lab. Clin. Med. 140:320-328.
111. O'Sullivan, C., Lewis, C.E., Harris, A.L., and McGee, J.O. 1993. Secretion of epidermal growth factor by macrophages associated with breast carcinoma. Lancet. 342:148-149.
112. van Kempen, L.C., and Coussens, L.M. 2002. MMP9 potentiates pulmonary metastasis formation. Cancer Cell. 2:251-252.
113. Curiel, T.J., et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10:942-949.
114. Schutyser, E., et al. 2002. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J. Biol. Chem. 277:24584-24593.
115. Bronte, V., et al. 2000. Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+ T cells. Blood. 96:3838-3846.
116. Saio, M., Radoja, S., Marino, M., and Frey, A.B. 2001. Tumor-infiltrating macrophages induce apoptosis in activated CD8(+) T cells by a mechanism requiring cell contact and mediated by both the cell-associated form of TNF and nitric oxide. J. Immunol. 167:5583-5593.
117. Young, M.R., et al. 1996. Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-beta and nitric oxide. J. Immunol. 156:1916-1922.
118. Liu, Y., et al. 2003. Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells. J. Immunol. 170:5064-5074.
119. Mencacci, A., et al. 2002. CD80+Gr-1+ myeloid cells inhibit development of antifungal Th1 immunity in mice with candidiasis. J. Immunol. 169:3180-3190.
120. Goni, O., Alcaide, P., and Fresno, M. 2002. Immunosuppression during acute Trypanosoma cruzi infection: involvement of Ly6G (Gr1(+))CD11b(+)immature myeloid suppressor cells. Int. Immunol. 14:1125-1134.
121. Marshall, M.A., et al. 2001. Mice infected with Schistosoma mansoni develop a novel non-T-lymphocyte suppressor population which inhibits virus-specific CTL induction via a soluble factor. Microbes Infect. 3:1051-1061.
122. Brys, L., et al. 2005. Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection. J. Immunol. 174:6095-6104.
123. Terrazas, L.I., et al. 2001. The schistosome oligosaccharide lacto-N-neotetraose expands Gr1(+) cells that secrete anti-inflammatory cytokines and inhibit proliferation of naive CD4(+) cells: a potential mechanism for immune polarization in helminth infections. J. Immunol. 167:5294-5303.
124. Giordanengo, L., et al. 2002. Cruzipain, a major Trypanosoma cruzi antigen, conditions the host immune response in favor of parasite. Eur. J. Immunol. 32:1003-1011.